What Is Semax? Uses, Risks, and FDA Status
What Is Semax?
Semax is a synthetic heptapeptide (seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is an analog of ACTH(4-10), a fragment of adrenocorticotropic hormone, but without the hormonal effects on cortisol. Semax has been approved as a prescription drug in Russia since 2011 for stroke recovery, cognitive impairment, and optic nerve atrophy.
How Does Semax Work?
Semax works primarily by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB in the hippocampus and cortex. BDNF promotes neuronal survival, synaptic plasticity, and the formation of new neural connections. Semax also modulates serotonergic, dopaminergic, and adrenergic neurotransmitter systems, which likely accounts for its reported effects on mood and focus. Additionally, it reduces neuroinflammation by modulating inflammatory cytokines and provides neuroprotection against oxidative stress in neural tissue (Ashmarin et al., Neurosci Behav Physiol, 2005).
What Is Semax Used For?
Based on published research and clinical use in Russia, Semax has been investigated for:
- Stroke recovery — Approved in Russia for cerebral ischemia; clinical studies show improved cognitive outcomes in stroke patients
- Cognitive enhancement — Used for focus, memory, and mental clarity in both clinical and nootropic contexts
- Neuroprotection — Protective effects against ischemic brain damage in animal models
- Anxiety and mood — Reported anxiolytic effects, though formal clinical data is limited
- Optic nerve atrophy — Approved indication in Russia for optic nerve conditions
- ADHD and cognitive impairment — Used off-label in some clinical settings for attention and executive function
What Are the Risks?
- Limited Western clinical data. Most published research comes from Russian institutions. Independent replication in Western settings is limited.
- Potential for overstimulation. Some users report restlessness, irritability, or insomnia, particularly at higher doses or with afternoon administration.
- Nasal irritation. When administered intranasally (the most common route), mild nasal irritation or dryness may occur.
- Hair loss. Anecdotal reports of temporary hair shedding exist, though this has not been confirmed in clinical studies.
- Unknown long-term effects in Western populations. While decades of Russian clinical use suggest a favorable safety profile, formal long-term studies meeting Western regulatory standards are lacking.
FDA Status
Semax was removed from the FDA's Category 2 list in April 2026 and is scheduled for PCAC review on July 24, 2026 for potential addition to the 503A bulks list. It is currently in a regulatory gray zone — no longer restricted, but not yet formally authorized for compounding in the US. It is not FDA-approved as a drug in the United States, though it holds prescription drug status in Russia.
Key Takeaway
Semax is a neuroprotective peptide with decades of clinical use in Russia and promising cognitive enhancement properties, currently awaiting a key FDA advisory committee decision for US compounding access.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.